• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

    2/14/24 5:07:22 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLLS alert in real time by email
    SC 13G/A 1 cellectis_13ga2.htm SC 13G/A
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    Cellectis S.A.

     

    (Name of Issuer)

    Ordinary Shares

     

    (Title of Class of Securities)

    15117K103

     

    (CUSIP Number)

    Long Focus Capital Management LLC
    207 Calle Del Parque
    A&M Tower, 8th Floor
    San Juan, PR 00912
    (787) 333-0240

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    December 31, 2023

     

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    o  Rule 13d-1(c)
    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     
             
    CUSIP No. 15117K103   13G   Page 2 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    LONG FOCUS CAPITAL MANAGEMENT, LLC
    46-2772035
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE, USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    4,487,293

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    4,487,293

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,487,293 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.3%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
     
     
             
    CUSIP No. 15117K103   13G   Page 3 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    LONG FOCUS CAPITAL MASTER, LTD.
    46-3004723
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    2,415,996

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    2,415,996

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,415,996 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.4%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    FI
       
     
     
             
    CUSIP No. 15117K103   13G   Page 4 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    CONDAGUA, LLC
    47-3021161
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE, USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    2,071,297

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    2,071,297

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,071,297 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.9%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    OO
       
     
     
             
    CUSIP No. 15117K103   13G   Page 5 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    JOHN B. HELMERS
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    4,487,293

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    4,487,293

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,487,293 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.3%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
     
     
             
    CUSIP No. 15117K103   13G   Page 6 of 10 Pages

             
    1.   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    A. GLENN HELMERS
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    o
    (b)    x
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
       

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    0
      6.  

    SHARED VOTING POWER

    2,071,297

      7.   SOLE DISPOSITIVE POWER
     
    0
      8.   SHARED DISPOSITIVE POWER
     
    2,071,297

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,071,297 shares

       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    o
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.9%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IN
       
     
     
             
    CUSIP No. 15117K103   13G   Page 7 of 10 Pages
             

    Item 1.

     

      (a) Name of Issuer
    CELLECTIS S.A.
         
      (b)

    Address of Issuer’s Principal Executive Offices
    8, rue de la Croix Jarry
    Paris, LLE-DE-FRANCE I0 750130
    France

         

    Item 2.

     

      (a)

    Name of Person Filing
    LONG FOCUS CAPITAL MANAGEMENT, LLC

    LONG FOCUS CAPITAL MASTER, LTD.

    CONDAGUA, LLC
    JOHN B. HELMERS
    A. GLENN HELMERS

         
      (b)

    Address of the Principal Office or, if none, residence
    207 CALLE DEL PARQUE

    A&M TOWER, 8TH FLOOR

    SAN JUAN, PR 00912

         
      (c) Citizenship
    Long Focus Capital Management, LLC, a Delaware single member limited liability company;
    Long Focus Capital Master, LTD., a Cayman Islands limited company;
    Condagua, LLC, a Delaware single member limited liability company;
    John B. Helmers, a United States citizen; and
    A. Glenn Helmers, a United States citizen.
         
      (d) Title of Class of Securities
    Ordinary Shares
         
      (e) CUSIP Number
    15117K103

     
     
             
    CUSIP No. 15117K103   13G   Page 8 of 10 Pages
             

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2023.

     

    Long Focus Capital Management, LLC, John B. Helmers, and A. Glenn Helmers directly own no Ordinary Shares. Pursuant to an investment management agreement, Long Focus Capital Management, LLC maintains investment and voting power with respect to the securities held by Long Focus Capital Master, Ltd. John B. Helmers controls Long Focus Capital Management, LLC, and has investment and voting power with respect to Condagua, LLC. A. Glenn Helmers controls Condagua, LLC.

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     
     
             
    CUSIP No. 15117K103   13G   Page 9 of 10 Pages
             

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     o.

    Instruction. Dissolution of a group requires a response to this item.

    NOT APPLICABLE

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    NOT APPLICABLE

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    NOT APPLICABLE

    Item 8.  Identification and Classification of Members of the Group.

    NOT APPLICABLE

    Item 9.  Notice of Dissolution of Group.

    NOT APPLICABLE

    Item 10.  Certification.

           
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
      (b)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
     
     
             
    CUSIP No. 15117K103   13G   Page 10 of 10 Pages
             

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      LONG FOCUS CAPITAL MANAGEMENT, LLC
       
      /s/ John B. Helmers
      John B. Helmers/Managing Member
       
      LONG FOCUS CAPITAL MASTER, LTD.
      BY: LONG FOCUS CAPITAL MANAGEMENT, LLC
    ITS: INVESTMENT ADVISER
       
      /s/ John B. Helmers
      John B. Helmers/Managing Member
       
      CONDAGUA, LLC
       
      /s/ A. Glenn Helmers
      A. Glenn Helmers/Managing Member
       
      JOHN B. HELMERS
       
      /s/ John B. Helmers
      John B. Helmers
       
      A. GLENN HELMERS
       
      /s/ A. Glenn Helmers
      A. Glenn Helmers
     
    Get the next $CLLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLLS

    DatePrice TargetRatingAnalyst
    3/17/2023$6.00Buy
    Bryan Garnier
    5/18/2022$10.00Neutral → Outperform
    Robert W. Baird
    1/6/2022$16.00Overweight → Equal-Weight
    Wells Fargo
    11/30/2021$20.00Mkt Outperform
    JMP Securities
    11/8/2021Outperform → Mkt Perform
    William Blair
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Baird
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $CLLS
    SEC Filings

    View All

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    8/4/25 4:35:08 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    8/4/25 4:30:06 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cellectis S.A.

    6-K - Cellectis S.A. (0001627281) (Filer)

    7/28/25 4:35:04 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

    Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025  Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025  AstraZeneca partnership: R&D activities are continuing to advance for the three programs initiated Appointment of Mr. André Muller as Director to Cellectis' Board of Directors Cash, cash

    8/4/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-343-5172 Inte

    7/28/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

    NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 57% of voting rights were exercised, resolutions 1 through 23 and resolutions 25 and 26 were adopted, while resolution 24 was rejected, consistent with the recommendations of the board of directors. The Cellectis shareholders' meeting appointed Mr. André Muller as a member of the Company's Board o

    6/26/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bryan Garnier initiated coverage on Cellectis with a new price target

    Bryan Garnier initiated coverage of Cellectis with a rating of Buy and set a new price target of $6.00

    3/17/23 9:01:09 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Cellectis from Neutral to Outperform and set a new price target of $10.00

    5/18/22 7:11:44 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cellectis from Overweight to Equal-Weight and set a new price target of $16.00

    1/6/22 5:50:31 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Leadership Updates

    Live Leadership Updates

    View All

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

    UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company

    11/4/24 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

    NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation

    8/7/24 2:00:00 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Financials

    Live finance-specific insights

    View All

    Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

    Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025  Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout expected in late 2025  AstraZeneca partnership: R&D activities are continuing to advance for the three programs initiated Appointment of Mr. André Muller as Director to Cellectis' Board of Directors Cash, cash

    8/4/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

    NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-343-5172 Inte

    7/28/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cellectis Reports Financial Results for the First Quarter 2025

    Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meetingCash position of $246 million as of March 31, 20251 provides runway into H2 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Ce

    5/12/25 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

    SC 13D/A - Cellectis S.A. (0001627281) (Subject)

    5/21/24 4:19:05 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

    SC 13G/A - Cellectis S.A. (0001627281) (Subject)

    2/14/24 5:07:22 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

    SC 13G/A - Cellectis S.A. (0001627281) (Subject)

    2/14/24 2:24:22 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care